Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue
+10.2%
EPS
+22.2%
Free cash flow
−4.83%

Quarter to September 2026, against a year earlier

69.96 1.25 +1.82%
Market cap
$16.8B
P/E
19.9×
Fwd P/E
20.2×
Dividend yield
—
F-score
7/9
Altman Z
12.68
Beneish M
−2.61
Dividend safety
n/a

Exelixis, Inc. (EXEL) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Exelixis, Inc. (EXEL) trades at a EV/FCF of 14.1×. Over the past ten years it has ranged from −10.2× (December 2015) to 62.2× (January 2018); the current reading is higher than 39% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 12.9× (4.82%)
FY2024 13.5× (65.32%)
FY2023 39.0× 120.91%
FY2022 17.6× 37.74%
FY2021 12.8× (54.26%)
FY2020 28.0× 219.84%
FY2019 8.8× (35.27%)
FY2018 13.5× (77.88%)
FY2017 61.2× 280.95%
FY2016 16.1× —

Quarterly newest first

Period EV/FCF Change
Sep 2026 11.8× 6.83%
Jun 2026 11.1× (2.89%)
Mar 2026 11.4× (11.37%)
Dec 2025 12.9× (5.35%)
43 more quarters

Against its own ten years

Low −10.2× High 62.2×
Ten-year median 16.3×
Current reading's percentile 32

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on EXEL